DURHAM, N.C., March 21, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that Jeffrey Abbey, president and chief executive officer, will present at the upcoming 21st Annual Future Leaders in the Biotech Industry conference. Mr. Abbey will provide a review of progress in the pivotal ADAPT Phase 3 clinical trial for AGS-003, Argos’s fully personalized immunotherapy currently in development for the treatment of metastatic renal cell carcinoma, and additional updates for the AGS-004 Phase 2 program in HIV. The conference will be held at the Millennium Broadway Hotel & Conference Center in New York City.
Help employers find you! Check out all the jobs and post your resume.
